Literature DB >> 17576839

In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.

Olivier Lortholary1, Eric Dannaoui, Dorothée Raoux, Damien Hoinard, Annick Datry, André Paugam, Jean-Louis Poirot, Claire Lacroix, Françoise Dromer.   

Abstract

The posaconazole MIC(90) for 1,903 yeast isolates from France was 1 microg/ml (range, < or =0.015 to 8 microg/ml). Ninety percent of isolates with fluconazole MICs of > or =8 microg/ml (n = 509) and 90% of those with voriconazole MICs of > or =2 microg/ml (n = 80) were inhibited by 2 and 8 microg/ml of posaconazole, respectively.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576839      PMCID： PMC2043210          DOI： 10.1128/AAC.00496-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

Authors:  Manuel Cuenca-Estrella; Dolores Rodriguez; Benito Almirante; Juliette Morgan; Ana Maria Planes; Manel Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Margarita Salvado; David W Warnock; Albert Pahissa; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2004-12-23       Impact factor: 5.790

2.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.

Authors:  Anna Maria Tortorano; Anna Prigitano; Emanuela Biraghi; Maria Anna Viviani
Journal:  J Antimicrob Chemother       Date:  2005-09-06       Impact factor: 5.790

4.  In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 6.  Posaconazole: a broad-spectrum triazole antifungal.

Authors:  Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

7.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803
View more
  8 in total

Review 1.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.

Authors:  A Sellami; H Sellami; S Néji; F Makni; S Abbes; F Cheikhrouhou; H Chelly; M Bouaziz; B Hammami; M Ben Jemaa; S Khaled; A Ayadi
Journal:  Mycopathologia       Date:  2010-12-19       Impact factor: 2.574

Review 3.  Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Authors:  Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Journal:  Drug Des Devel Ther       Date:  2010-11-04       Impact factor: 4.162

4.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

5.  Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.

Authors:  David Lebeaux; Fanny Lanternier; Caroline Elie; Felipe Suarez; Agnès Buzyn; Jean-Paul Viard; Marie-Elisabeth Bougnoux; Marc Lecuit; Vincent Jullien; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

Review 6.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Candida albicans and Candida dubliniensis Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles.

Authors:  Rania Ayadi; Emilie Sitterlé; Christophe d'Enfert; Eric Dannaoui; Marie-Elisabeth Bougnoux
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

8.  Distribution, antifungal susceptibility pattern and intra-Candida albicans species complex prevalence of Candida africana: A systematic review and meta-analysis.

Authors:  Sanaz Aghaei Gharehbolagh; Bahareh Fallah; Alireza Izadi; Zeinab Sadeghi Ardestani; Pooneh Malekifar; Andrew M Borman; Shahram Mahmoudi
Journal:  PLoS One       Date:  2020-08-20       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.